SCHEMBL4524692

SCHEMBL4524692

Cc1c(COc2ccccc2)cncc1-c1ccc2c(c1)c(C(=O)Nc1ccncc1)nn2COCC[Si](C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 4/20 0.34
HPGD P15428 2/20 0.34
GAA P10253 1/20 0.34
RIPK1 Q13546 1/20 0.34
GRM5 P41594 1/20 0.34
DGAT1 O75907 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
TSHR P16473 1/20 0.33
ROCK1 Q13464 3/20 0.33
DGAT2 Q96PD7 1/20 0.33
POLB P06746 1/20 0.33
PAK1 Q13153 1/20 0.32
AKT1 P31749 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL951815 0.87 GRM5 (0.39) MAPTLMNARIPK1GRM5DGAT1
SCHEMBL954050 0.85 GRM5 (0.37) MAPTRIPK1GRM5ROCK1PAK1
SCHEMBL4531463 0.84 GRM5 (0.36) MAPTRIPK1GRM5PAK1
SCHEMBL951128 0.83 ABL1 (0.42) MAPTSMN1; SMN2GRM5ROCK1
SCHEMBL4524532 0.83 MCL1 (0.39) SMN1; SMN2ALDH1A1
SCHEMBL4521537 0.79 FLT1 (0.44) ROCK1DGAT2
SCHEMBL953701 0.79 PIK3C3 (0.41) MAPTGRM5KMT2AMAPK1MEN1
SCHEMBL27655692 0.79 DYRK1A (0.43) MAPTSMN1; SMN2DGAT1
SCHEMBL4518203 0.78 LMNA (0.39) LMNAHPGDALDH1A1KDM4E
SCHEMBL6277247 0.77 MMP9 (0.43) KMT2AMEN1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482342-B2 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2009-01-27 US disclosed
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors SANOFI-AVENTIS (FR) 2006-01-05 US disclosed
EP-1549620-A1 INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS Sanofi-Aventis (FR) 2005-07-06 EP disclosed
WO-2004031158-A1 INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS SANOFI-AVENTIS (FR) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004000-A1 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors CDK2, CDK1, CDK4 L3MBTL1 4165/4885MAPT 2661/4885SMN1; SMN2 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.